Cofepris implementing a new platform for processing the research and clinical trials digitally, named Digital Platform for Research and Clinical Trials (DIGIPRiS) with an objective as a strategic attraction for the medical industry.
DIGIPRiS applies full transparency to all documents with no intermediary parties involved during the evaluation procedure. Besides, this digital platform is expected to shorten the evaluation period by up to 75% compared to the traditional method which also involves face-to-face meetings with Cofepris. All specialists who carry out clinical research on human beings were invited to utilize DIGIPRiS for new protocol requests and change submissions for the authorized protocols. The submissions via the digital platform can also be used for entry procedures, status review, and receipt of resolutions.
The advancement procedure assists both the public and private sectors to obtain digital resolution in 6 steps and soon, there will be no more physical entry for research protocol requests on human beings.
Technology evolution in developing research and expanding disease knowledge via DIGIPRiS helped to tighten the industry gap by the boosted responding time for the evaluation period and certain person-centered cases. This tactical strategy will attract bigger investments for the research sector in the medical industry.
Contact us at info@arqon.com for more information.